AUG 7, 2026 · JOURNAL ARTICLE
Wogonoside alleviates metabolic dysfunction-associated steatohepatitis by modulating AMPK and xCT/GPX4 pathways to restrain lipid dysregulation and ferroptosis
Frontiers in Pharmacology
Preclinical study in animal and cell models with mechanistic endpoints; no human trials reported, limiting clinical applicability despite sound experimental design.
Reported
Study model systemsHFFD-induced mouse model and FFA-induced He…